[1]
|
A. Velázquez, L. Martínez, V. Abrego, M. A. Balboa, L. A. Torres, B. Camacho, S. Díaz-Barriga, A. Romero, R. López-Casta?ares and E. Angeles, “Synthesis and Antihypertensive Effects of New Methylthiomorpholinphenol Derivatives,” European Journal of Medicinal Chemistry, Vol.43, No. 3, 2008, pp. 486-500.
doi:10.1016/j.ejmech.2007.04.003
|
[2]
|
A. Ma. Velázquez, G. Díaz, A. Ramírez, R. Hernández, H. Santillán L. Martínez, V. Abrego, M.A. Balboa, L.A. Torres, B. Camacho, S. Díaz-Barriga, A. Romero, R. López-Casta?ares, A. Due?as-González, G. Cabrera and E. Angeles, “A Novel One Pot, Solvent-Free Mannich Synthesis of Methylpiperidinyl Phenols, Methylphenylmorpholinyl Phenols and Methylthiophenylmorpholinyl Phenols Using Infrared Light Irradiation,” Arkivoc, Vol. ii, No. 2006, pp. 150-161.
|
[3]
|
E. Angeles, V. H. Vázquez, O. Vázquez, A. Ma. Velázquez, A. Ramírez, L. Martínez, S. Díaz-Barriga, A. Romero, G. Cabrera, R. López-Casta?ares and A. Due?as, “Computational Studies of 1-Hydrazinophthalazine (Hydralazine) as an Antineoplasic Agent. Docking Studies on Methyltransferase,” Letters in Drug Design and Discovery, Vol. 2, No. 4, 2005, pp. 282-286.
doi:10.2174/1570180054038413
|
[4]
|
K. Hudson and G. Ronquist, “Medical Use of Captopril for the Treatment and Prophylaxis of Cancer,” Patent No.WO2003077909, 2003.
|
[5]
|
Y. K. Chae, M. E. Valsecchi, J. Kim, A. L. Bianchi, D. Khemasuwan, A. Desai and W. Tester, “Therapeutic Combination and Methods of Treatment with a dll4 Antagonist and an Anti-Hypertensive Agent,” Cancer Investigation, Vol. 29, No. 9, 2011, pp. 585-593.
doi:10.3109/07357907.2011.616252
|
[6]
|
D. Kültz, “Molecular and Evolutionary Basis of the Cellular Stress Response,” Annual Review of Physiology, Vol. 67, 2005, pp. 225-257.
doi:10.1146/annurev.physiol.67.040403.103635
|
[7]
|
S. Fulda and K. M. Debatin, “Extrinsic versus Intrinsic Apoptosis Pathways in Anticancer Chemotherapy,” Oncogene, Vol. 25, No. 34, 2006, pp. 4798-4811.
doi:10.1038/sj.onc.1209608
|
[8]
|
V. Zuzarte-Luis and J. M. Hurle, “Programmed Cell Death in the Developing Limb,” The International Journal of Developmental Biology, Vol. 6, No. 7, 2002, pp. 871-876.
|
[9]
|
P. Meier, A. Finch and G. Evan, “Apoptosis in Development,” Nature, Vol. 407, No. 6805, 2000, pp. 796-801.
doi:10.1038/35037734
|
[10]
|
M. Raff, “Cell Suicide for Beginners,” Nature, Vol. 396, No. 6707, 1998, pp.119-122. doi:10.1038/24055
|
[11]
|
P. Krammer, “CD95’s Deadly Mission in the Immune System,” Nature, Vol. 407, No. 6805, 2000, pp. 789-795.
doi:10.1038/35037728
|
[12]
|
A. Saraste and K. Pulkki, “Morphologic and Biochemical Hallmarks of Apoptosis,” Cardiovascular Research, Vol. 45, No. 3, 2000, pp. 528-37.
doi:10.1016/S0008-6363(99)00384-3
|
[13]
|
U. Sartorius, I. Schmitz and P. Krammer, “Molecular Mechanisms of Death-Receptor-Mediated Apoptosis,” ChemBioChem, Vol. 2, No. 1, 2001, pp. 20-29.
doi:10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.0.CO;2-X
|
[14]
|
M. Lenardo, K. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang and L. Zheng, “Mature T Lymphocyte Apoptosis: Immune Regulation in a Dynamic and Unpredictable Antigenic Environmental,” Annual Review of Immunology, Vol. 17, 1999, pp. 221-253.
doi:10.1146/annurev.immunol.17.1.221
|
[15]
|
S. Nagata, “Fas Ligand-Induced Apoptosis,” Annual Review of Genetics, Vol. 33, 1999, pp. 29-55.
doi:10.1146/annurev.genet.33.1.29
|
[16]
|
K. Bailey, H. Cook and C. McMaster, “The Phospholipid Scramblase PLSCR1 Increases UV Induced Apoptosis Primarily through the Augmentation of the Intrinsic Apoptotic Pathway and Independent of Direct Phosphorylation by Protein Kinase C δ,” Biochimica et Biophysica Acta, Vol. 1733, No. 2-3, 2005, pp. 199-209.
doi:10.1016/j.bbalip.2004.12.013
|
[17]
|
J. J. Alam, “Apoptosis: Target for Novel Drugs,” Trends in Biotechnology, Vol. 21, No. 11, 2003, pp. 479-483.
doi:10.1016/j.tibtech.2003.08.006
|
[18]
|
J. A. Folkes, K. Ahmadi, K. Alderton, S. Alix, J. S. Baker, G. Box, S. Chuckowree, A. Clarke, P. Depledge, A. S. Eccles, S. Friedman, A. Hayes, C. Hancox, A. Kugendradas, L. Lensun, P. Moore, G. A. Olivero, J. Pang, S. Patel, H. G. Pergl-Wilson, I. F. Raynaud, A. Robson, N. Saghir, L. Salphati, S. Sohal, M. H. Ultsch, M. Valenti, H. J. Wallweber, N. C. Wan and C. Wiesmann, “The Identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer,” Journal of Medicinal Chemistry, Vol. 51, No. 18, 2008, pp. 5522-5532. doi:10.1021/jm800295d
|
[19]
|
H. Qiuxia, Z. Xingshang, S. Mei, Z. Jing, Z. Shangli and M. Junying, “Novel Morpholin-3-One Derivatives Induced Apoptosis and Elevated the Level of P53 and Fas in A549 Lung Cancer Cells,” Bioorganic & Medicinal Chemistry, Vol. 15, No. 11, 2007, pp. 3889-3895.
doi:10.1016/j.bmc.2007.03.008
|
[20]
|
M. Hayakawa, H. Kaizawa, H. Moritomo, T. Koizumi, T. Ohishi, M. Okada, S. Tsukamoto, P. Parker, P. Workman and M. Waterfield, “Synthesis and Biological Evaluation of 4-Morpholino-2-phenylquinazolines and Related Derivatives as Novel PI3 Kinase p110α Inhibitors,” Bioorganic & Medicinal Chemistry, Vol. 14, No. 20, 2006, pp. 6847-6858. doi:10.1016/j.bmc.2006.06.046
|
[21]
|
D. Yin, M. Woodruff, Y. Zhang, S Whaley, J. Miao, K. Ferslew, J. Zhao and C. Stuart, “Morphine Promotes Jurkat Cell Apoptosis through Pro-Apoptotic FADD/P53 and Anti-Apoptotic PI3K/Akt/NF-nB Pathways,” Journal of Neuroimmunology, Vol. 174, No. 1, 2006, pp. 101-107.
doi:10.1016/j.jneuroim.2006.02.001
|
[22]
|
V. Dzau, A. J. Folkes, K. Ahmadi, W. K. Alderton, S. Alix, S. J. Baker, G. Box, I. S. Chuckowree, P. A. Clarke, P. Depledge, S. A. Eccles, L. S. Friedman, A. Hayes, T. C. Hancox, A. Kugendradas, L. Lensun, P. Moore, A. G. Olivero, J. Pang, S. Patel, G. H. Pergl-Wilson, F. I. Raynaud, A. Robson, N. Saghir, L. Salphati, S. Sohal, M. H. Ultsch, M. Valenti, H. J. Wallweber, N. C. Wan, C. Wiesmann, P. Workman, A. Zhyvoloup, M. J. Zvelebil and S. J. Shuttleworth. “The Identification of 2-(1H-Indazol-4-yl)-6-(4-Methanesulfonyh-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyperidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer,” Journal of Medicinal Chemistry, Vol. 51, No. 18, 1994, pp. 5522-5532.
|
[23]
|
R. Wang, A. Zagariya, E. Ang, O. Ibarra-Sunga and B. D. Uhal, “Fas-Induced Apoptosis of Alveolar Epithelial Cells Requires ANG. II II Generation and Receptor Interaction,” American Journal of Physiology. Lung Cellular and Molecular Physiology, Vol. 277, Pt. 1, 1999, pp. 1245-1250.
|
[24]
|
A. Molteni, W. Ward, C. Ts’ao, N. Solliday and M. Dunne, “Monocrotaline-Induced Pulmonary Fibrosis in Rats: Amelioration by Captopril and Penicillamine,” Proceedings of the Society for Experimental Biology and Medicine, Vol. 180, No. 1, 1985, pp. 112-120.
|
[25]
|
H. J. Neo, I. E. Ager, W. P. Angus, J. Zhu, B. C. Herath and C. Christophi, “Changes in the Renin Angiotensin System during the Development of Colorectal Cancer Liver Metastases,” Cancer, Vol. 10, No. 134, 2010, pp. 1-11.
|